Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VCAM1 | P19320 | 13/20 | 0.48 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.45 |
| ▸ | HPN | P05981 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.41 |
| ▸ | GLRA3 | O75311 | 1/20 | 0.37 |
| ▸ | GLRB | P48167 | 1/20 | 0.37 |
| ▸ | HMGCR | P04035 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | RECQL | P46063 | 1/20 | 0.35 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6438215 | 1.00 | VCAM1 (0.48) | VCAM1GPR55HPNMAPTALOX15 | |
| SCHEMBL9158690 | 0.78 | HPN (0.44) | VCAM1GPR55HPNMAPTALOX15 | |
| SCHEMBL9680927 | 0.77 | HPN (0.41) | VCAM1HPNMAPTALOX15SIRT5 | |
| SCHEMBL9158352 | 0.76 | VCAM1 (0.46) | VCAM1GPR55HPNMAPTALOX15 | |
| SCHEMBL9314272 | 0.76 | MAOB (0.47) | LMNA | |
| SCHEMBL9330356 | 0.76 | HPN (0.47) | VCAM1GPR55HPNMAPTALOX15 | |
| SCHEMBL9847649 | 0.74 | VCAM1 (0.46) | VCAM1GPR55HPNMAPTALOX15 | |
| SCHEMBL9163349 | 0.73 | HPN (0.45) | VCAM1HPNMAPTALOX15SIRT5 | |
| SCHEMBL9328104 | 0.73 | HPN (0.52) | VCAM1HPNMAPTALOX15SIRT5 | |
| SCHEMBL8823307 | 0.73 | HPN (0.52) | VCAM1HPNMAPTALOX15SIRT5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4658247-A1 | COMPOSITIONS AND METHODS FOR TREATING HYPERPROCALCITONEMIA | Vivacelle Bio, Inc. (US) | 2025-12-10 | — | — | EP | disclosed |
| US-20250195630-A1 | COMPOSITIONS, METHODS AND USES OF ALPHA 1-ANTITRYPSIN FOR TREATMENT OF GRAFT VERSUS HOST DISEASE | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE | 2025-06-19 | — | — | US | disclosed |
| US-20250101131-A1 | COMPOSITIONS AND METHODS OF USE FOR ALPHA-1 ANTITRYPSIN FUSION POLYPEPTIDES | KONKUK UNIVERSITY (KR) | 2025-03-27 | — | — | US | disclosed |
| US-20240315969-A1 | COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING MULTIPLE ORGAN DYSFUNCTION SYNDROME | VIVACELLE BIO INC. | 2024-09-26 | — | — | US | disclosed |
| WO-2024163181-A1 | COMPOSITIONS AND METHODS FOR TREATING HYPERPROCALCITONEMIA | VIVACELLE BIO, INC. (US) | 2024-08-08 | — | — | WO | disclosed |
| US-12036321-B2 | Compositions and methods for treating or preventing multiple organ dysfunction syndrome | VIVACELLE BIO, INC. (US) | 2024-07-16 | — | — | US | disclosed |
| US-12030958-B2 | Compositions and methods of use of alpha-1 antitrypsin fusion polypeptides | THE REGENTS OF THE UNIVERSITY OF COLORADO (US) | 2024-07-09 | — | — | US | disclosed |
| US-20240009126-A1 | COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING MULTIPLE ORGAN DYSFUNCTION SYNDROME | VIVACELLE BIO INC. | 2024-01-11 | — | — | US | disclosed |
| CN-115715221-A | Compositions and methods for treating or preventing multiple organ dysfunction syndrome | 维生宝生物股份有限公司 | 2023-02-24 | — | — | CN | disclosed |
| EP-4126250-A1 | COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING MULTIPLE ORGAN DYSFUNCTION SYNDROME | Vivacelle Bio, Inc. (US) | 2023-02-08 | — | — | EP | disclosed |
| US-20220204646-A1 | Compositions and Methods of Use of Alpha-1 Antitrypsin Fusion Polypeptides | KONKUK UNIVERSITY (KR) | 2022-06-30 | — | — | US | disclosed |